Hypera Sa S/Adr (HYPMY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Welcome to Hypera Pharma's video conference that will discuss the earnings for the second quarter 2025. We have with us Mr. Bruno Oliveira, CEO, and Mr. Ramon Sanchez, CFO and Director of Investor Relations. This event will be recorded and the recording can be accessed on the website of the company, ri.hypera.com.br. All participants will only be watching the video conference during the presentation. And after that, we'll follow up with a Q&A session when we're going to give you more instructions. Before we move forward, I'd like to highlight that Information contained in this conference call may contain projections or statements about future expectations. These statements are subject to known and unknown risks and uncertainties that may lead these expectations to not occur or to be substantially different from expected. Now I'll give the floor to Mr. Breno Oliveira, who will start the presentation. Mr. Breno, you have the floor. Good morning, everyone. Thank you for joining our second quarter 2025 earnings conference call. I'll begin the presentation on slide three. This quarter, our sellout grew 5.5%. In the retail market, above the 5.2% growth of our addressable market during the same period, we experienced significant acceleration in sell-out growth in May, June, and July, with an average growth of 8% in these three months. The sellout acceleration was driven by the market recovery in the categories where we operate after a weaker sales performance in April, as well as by the contribution of recent product launches and increased marketing investments mainly in digital media. Our sellout growth did not translate into net revenue growth due to the lingering impact of the working capital optimization process, which we successfully...